Insight Molecular Diagnostics Inc (IMDX)

Insight Molecular Diagnostics Inc. is a U.S.-based precision diagnostics company focused on developing and commercializing molecular tests for oncology and transplant monitoring, with international operations as well. Its portfolio includes laboratory developed tests, kitted research-use-only tests, and kitted clinical tests. Key programs include DetermaCNI, a blood-based tool designed to detect early cancer progression after the first treatment cycle, and DetermaIO, a gene expression assay intended to evaluate the tumor microenvironment and help predict response to immunotherapy. The company also offers VitaGraft Kidney and VitaGraft Liver, blood-based transplant monitoring tests that measure donor-derived cell-free DNA for kidney and liver transplantation, along with GraftAssure, a dd-cfDNA test based on droplet digital PCR technology. In addition, it provides biomarker discovery, assay development, clinical trial support, and related testing services. The company, formerly known as OncoCyte Corporation, was incorporated in 2009 and is headquartered in Nashville, Tennessee.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.